Imsidolimab - CISMeF

Preferred Label : Imsidolimab;

NCIt definition : A humanized monoclonal antibody directed against the interleukin-36 receptor (IL-36R), with potential anti-inflammatory and immunomodulatory activities. Upon administration, imsidolimab targets, binds to and prevents the activity of IL-36R by the pro-inflammatory cytokine IL-36. This prevents IL-36/IL-36R-mediated signaling pathways. This may inhibit skin inflammation in which the IL-36/IL-36R plays a key role. IL-36 is highly upregulated in certain skin inflammatory conditions.;

UNII : KX89J0DFZ8;

CAS number : 2102543-86-0;

Molecule name : ANB-019;

NCI Metathesaurus CUI : CL1642810;

Details

Origin ID

C177088;

UMLS CUI

C5447575;

Currated CISMeF NLP mapping
- Imsidolimab [SMS substance]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
has_target
- Interleukin-1 Receptor-Like 2 [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients